Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This webpage provides access options for JAMA Dermatology but does not contain research findings or results.

This study found that using an antimicrobial lotion for 18 months may reduce inflammation and potentially partially reverse hair loss in men with androgenetic alopecia.

This study found that androgen receptor expression varied across different types of skin appendage tumors, with specific expression patterns noted in sebaceous and sweat gland tumors but absent in hair follicle tumors.

This study's meta-analysis reported that PRP injections significantly increased hair density compared to baseline and placebo in androgenetic alopecia patients, supporting its use as a beneficial treatment.

This review describes the molecular interactions between androgens and Wnt/ß-catenin signaling in androgenetic alopecia but reports no new experimental or clinical findings; the authors discuss potential Wnt/ß-catenin-targeted treatments for hair growth.

This study found that in androgenetic alopecia, reduced stem cell factor production by dermal papilla cells may lead to decreased pigmentation in hair follicles.

This study observed that autologous bone marrow derived mononuclear cells and follicular stem cells were both safe and effective for improving resistant alopecia areata and androgenetic alopecia, with no serious adverse events.

This study found that topical melatonin solution was associated with positive effects on hair density and reduction in hair loss for androgenetic alopecia, with good tolerability reported in several clinical trials.

Topical minoxidil is a safe and effective treatment for hair loss caused by androgenetic alopecia.

This article reviews current guidelines for managing androgenetic alopecia and highlights the need for guidelines tailored to Japan; it reports no new clinical results.

This study reported that the aqueous ethanol extract of Lygodii Spora demonstrated in vitro testosterone 5alpha-reductase inhibition and in vivo anti-androgenic activity, potentially due to oleic, linoleic, and palmitic acids.

Testosterone causes hair loss in AGA mice, which are good for testing baldness treatments, and both minoxidil and cyproterone acetate can prevent this hair loss.

This study found that a ceria nanozyme-integrated microneedles patch accelerated hair regeneration in an androgenetic alopecia mouse model more effectively than minoxidil, with reduced application frequency and minimal skin damage.

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

This study found that higher BMI was significantly associated with more severe hair loss in men with male-pattern and early-onset androgenetic alopecia.

This study found that patients with severe vertex pattern androgenetic alopecia had significantly higher carotid intima-media thickness, suggesting an increased risk of subclinical atherosclerosis compared to other alopecia patterns and healthy controls.

This study evaluated the effect of 2% ketoconazole lotion for androgenetic alopecia, but the results regarding its effectiveness on clinical appearance remained unclear.

This review discusses nonsteroidal selective androgen receptor modulators and their potential therapeutic applications but reports no new clinical findings.

In this study, androgen deprivation, particularly through finasteride treatment, effectively reduced chronic bacterial prostatitis severity in rats, suggesting potential for improved treatment modalities combining finasteride and levofloxacin.

This review summarizes existing research on the use of finasteride for treating androgenetic alopecia in men, reporting its effectiveness at 1 mg/day and a strong safety profile, but presents no new findings.

This study suggests 5α‐androstan‐3α‐17β‐diol may be the true inducer of kidney enzymes in certain mice, while its induction mechanism likely involves pinocytosis rather than a receptor protein.

This study found that topical valproic acid significantly increased hair count in male patients with moderate androgenetic alopecia compared to placebo over 24 weeks.

This study found that among middle-aged Korean women, those with metabolic syndrome had a higher risk of androgenetic alopecia, while no significant association was observed in men.

This study found that both men and women with androgenic alopecia had significantly higher triglycerides, total cholesterol, and LDL-C and lower HDL-C levels than controls, suggesting increased dyslipidemia prevalence.

This study found that administering the gut bacterium Thauera sp. strain GDN1 to mice significantly reduced their serum androgen levels, indicating gut bacteria may influence androgen metabolism.

This review analyzed clinical trial protocols for platelet-rich plasma preparation in hair loss treatment, finding inconsistent and insufficient reporting that complicates comparison and efficacy determination.

In this study, researchers found that the prevalence of androgenetic alopecia was higher in their sample compared to other studies in Asian and Caucasian populations, and it was linked with age-related severity.

This study reported that Turkish males with male pattern androgenetic alopecia had significantly lower zinc and copper levels in their hair compared to healthy controls, suggesting these imbalances may play a role in the condition's etiology.

In this study, transgenic male mice over-expressing the androgen receptor in mesenchymal stem cells showed reduced fat mass and improved glucose clearance, suggesting enhanced androgen sensitivity may alter body composition.

This study found that nuclear androgen receptors are not necessary for androgen self-administration, suggesting that plasma membrane receptors might be involved.